Schulak J A, Mayes J T, Hricik D E
Transplantation Service, University Hospitals of Cleveland, OH 44106.
Transplant Proc. 1991 Aug;23(4):2119-22.
In summary, we believe that our experience with concomitant use of OKT3 and either reduced-dose CyA for treatment of renal allograft rejections or full-dose CyA therapy for treatment of liver allograft rejection is both safe and possibly more effective in reversing allograft rejection than use of the antibody alone. This strategy has also allowed us to use this MAb therapy without incurring the untoward consequence of the development of hightiter anti-OKT3 antibodies that could preclude its subsequent reuse.
总之，我们认为，我们在同时使用OKT3和低剂量环孢素A治疗肾移植排斥反应或使用全剂量环孢素A治疗肝移植排斥反应方面的经验是安全的，而且在逆转移植排斥反应方面可能比单独使用抗体更有效。这种策略还使我们能够使用这种单克隆抗体疗法，而不会产生高滴度抗OKT3抗体的不良后果，否则可能会妨碍其后续再次使用。
